Example: bankruptcy
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ABRAXANE safely and effectively. See full prescribing
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - …
media.celgene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OTEZLA safely and effectively. See full prescribing information for
Reference ID: 3976113 - Celgene
media.celgene.comFor patients whose baseline counts are WBC <3.0 x109/L, ANC<1.5 x109/L, or platelets <75.0 x109/L, base dose adjustments on nadir counts and bone marrow biopsy cellularity
MULTIPLE MYELOMA (MM) - Celgene
media.celgene.comArea of Research Phase 1 Phase 2 Phase 3 Post-Approval Research C C F P- esear C- C- T T appr LYMPHOMA REVLIMID® (lenalidomide) Mantle cell lymphoma: Relapsed/refractory . . . . . . . . . .
MEDICATION GUIDE - media.celgene.com
media.celgene.comCall your healthcare provider or get medical help right away if you get any of the following during treatment with POMALYST: Signs or symptoms of a blood clot in the lung, arm, or leg may include: shortness of breath, chest pain, or
HIGHLIGHTS OF PRESCRIBING INFORMATION ... - …
media.celgene.com4 Table 1: Dose Adjustments for Hematologic Toxicities for MM Platelet counts Thrombocytopenia in MM When Platelets Recommended Course .
MEDICATION GUIDE REVLIMID - Celgene
media.celgene.com42 MEDICATION GUIDE REVLIMID® (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID? Before you begin taking REVLIMID, you must read and agree to all of the instructions in the REVLIMID
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
media.celgene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use POMALYSTsafely and effectively. See full …
Related documents
Reference ID: 3366104 - ZEVALIN® (ibritumomab …
www.zevalin.comfull prescribing information warning: serious infusion reactions, prolonged and severe cytopenias, and severe cutaneous and mucocutaneous reactions
HYDRODIURIL (HYDROCHLOROTHIAZIDE)
www.hypertensionmeds.comHydroDIURIL® (Hydrochlorothiazide) 7897450 4 ADVERSE REACTIONS The following adverse reactions have been reported and, within each category, are listed in order of ...
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.astellas.us4 5 WARNINGS AND PRECAUTIONS 5.1 Hepatic Adverse Drug Reactions Hepatic adverse drug reactions (e.g., elevations in alanine aminotransferase (ALT), …
NDA 021470 Finacea Gel FDA Approved 5 August …
labeling.bayerhealthcare.comNDA 021470 Finacea Gel FDA Approved 5 August 2016.doc 6.2 Post-Marketing Experience The following adverse reactions have been identified post approval of FINACEA Gel.
Reference ID: 3340037 - Food and Drug …
www.accessdata.fda.govsevere or worsening liver tests. (2.3, 5.4) prolonged cutaneous r
NEW ZEALAND DATA SHEET 1. FENPAED ORAL …
www.medsafe.govt.nzCombination use of ACE inhibitors or angiotensin receptor antagonists, antiinflammatory drugs and thiazide diuretics The use of an ACE inhibiting drug (ACE-inhibitor or angiotensin receptor antagonist, an anti-
NEW ZEALAND DATA SHEET 1. MAXIGESIC TABLET
www.medsafe.govt.nzoccur without warning. These serious adverse events are idiosyncratic and are independent of dose or duration of use. Patients should be advised of the signs and symptoms of serious skin
DRUG NAME: SUNItinib - BC Cancer
www.bccancer.bc.cacross blood brain barrier? animal studies suggest that SUNItinib is able to cross the blood brain barrier : volume of distribution . 2230 L : Distribution